By Sy Mukherjee and Clifton Leaf
December 5, 2016

Good morning, readers.

I hope you had a wonderful weekend. Cliff is on his way back from the Fortune and Time Global Forum in Rome, so I’ll be filling in once again (you can read complete coverage of the event here).

Over the weekend, researchers, investors, and experts from around the world congregated for the American Society of Hematology’s (ASH) annual meeting. ASH 2016 has been one of the most anticipated scientific conventions of the year, with companies like Novartis, Kite, and Juno presenting critical new data about a next-gen set of drugs that are being tested in numerous blood cancers.

The companies jockeying for a first-to-market advantage in the space have encountered plenty of twists and turns along the way—and it appears that pharma giant Novartis may well achieve its original goal of a pioneering FDA approval for its own experimental treatment.

Read on for my write-up and more of the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

SPONSORED FINANCIAL CONTENT

You May Like